<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27223641</article-id><article-id pub-id-type="pmc">4976950</article-id><article-id pub-id-type="doi">10.5935/abc.20160082</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group><subject>Electrophysiology/Arrhythmias</subject></subj-group></subj-group></article-categories><title-group><article-title>Colchicine to Reduce Atrial Fibrillation in the Postoperative Period
of Myocardial Revascularization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zarpelon</surname><given-names>Camila Stuchi</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Netto</surname><given-names>Miguel Chomiski</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Jorge</surname><given-names>Jos&#x000e9; Carlos Moura</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Fabris</surname><given-names>C&#x000e1;tia Carolina</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Desengrini</surname><given-names>Dieli</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Jardim</surname><given-names>Mariana da Silva</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Diego Guedes</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1">Irmandade da Santa Casa de Miseric&#x000f3;rdia de Curitiba, Curitiba,
PR - Brazil</aff></contrib-group><author-notes><corresp id="c1"><bold>Mailing Address: Camila Stuchi Zarpelon,</bold> Hospital
Santa Casa de Curitiba. Jeremias Maciel Perretto, Campo Comprido. Postal Code
81210-310, Curitiba, PR - Brazil. E-mail:
<email>camilastuchi@cardiol.br</email>, <email>camilastuchi@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>7</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><volume>107</volume><issue>1</issue><fpage>4</fpage><lpage>9</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>05</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The high prevalence of atrial fibrillation (AF) in the postoperative period
of myocardial revascularization surgery increases morbidity and
mortality.</p></sec><sec><title>Objective</title><p>To assess the efficacy of colchicine to prevent AF in the postoperative
period of myocardial revascularization surgery, the impact of AF on hospital
length of stay and death, and to identify its risk factors.</p></sec><sec><title>Methods</title><p>Between May 2012 and November 2013, 140 patients submitted to myocardial
revascularization surgery were randomized, 69 to the control group and 71 to
the colchicine group. Colchicine was used at the dose of 1 mg orally, twice
daily, preoperatively, and of 0.5 mg, twice daily, until hospital discharge.
A single dose of 1 mg was administered to those admitted 12 hours or less
before surgery.</p></sec><sec><title>Results</title><p>The primary endpoint was AF rate in the postoperative period of myocardial
revascularization surgery. Colchicine group patients showed no reduction in
AF incidence as compared to control group patients (7.04% versus 13.04%,
respectively; p = 0.271). There was no statistically significant difference
between the groups regarding death from any cause rate (5.6% versus 10.1%; p
= 0,363) and hospital length of stay (14.5 &#x000b1; 11.5 versus 13.3
&#x000b1; 9.4 days; p = 0.490). However, colchicine group patients had a
higher infection rate (26.8% versus 8.7%; p = 0.007).</p></sec><sec><title>Conclusion</title><p>The use of colchicine to prevent AF after myocardial revascularization
surgery was not effective in the present study. Brazilian Registry of
Clinical Trials number RBR-556dhr.</p></sec></abstract><kwd-group><kwd>Colchicine/therapeutic use</kwd><kwd>Atrial Fibrillation/mortality</kwd><kwd>Myocardial Revascularization</kwd><kwd>Postoperative Period</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Atrial fibrillation in the postoperative period of myocardial revascularization
surgery (AF-POMR) occurs in 10% to 65% of patients,<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r5" ref-type="bibr">5</xref></sup> increasing
morbidity and mortality after surgery.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> It is associated
with an increase in hospital length of stay, and, thus, in costs,<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup> and can cause
serious clinical complications, such as hypotension, heart failure, stroke and other
thromboembolic disorders.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p><p>Although not completely understood, the electrophysiological mechanism of AF-POMR is
believed to be reentry. Some complications inherent in the postoperative period can
be the trigger in patients predisposed to AF. Perioperative atrial trauma,
pericardial inflammatory process secondary to surgical manipulation, autonomic
disorder and plasma volume changes are some predisposing factors.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r11" ref-type="bibr">11</xref></sup></p><p>Colchicine is the classic drug to treat gout, in addition to being part of the
management of Mediterranean fever and Behcet's disease. It is usually classified as
an anti-inflammatory agent, although its mechanism of action does not involve the
arachidonic acid metabolic pathway. Colchicine binds to non-polymerized tubulin,
forming a stable complex that effectively inhibits the dynamic of microtubules,
depolymerizing them. Thus, any process requiring changes in the cell cytoskeleton,
such as cellular mitosis, exocytosis and neutrophil motility, is affected.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> In addition, colchicine has an
important effect on atrial myocytes, changing the atrial response to autonomic
effects (reducing the sympathetic activity and increasing the parasympathetic
one).<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup></p><p>A COPPS substudy, published by Imazio et al.,<sup><xref rid="r6" ref-type="bibr">6</xref></sup> has assessed the use of colchicine to prevent atrial
fibrillation (AF) in the postoperative period of cardiac surgery. A reduction from
22% to 12% was observed in the AF rate as compared to the control group (p = 0.021),
in addition to a reduction in hospital length of stay (p = 0.04) and rehabilitation
time (p = 0.009)<sub>.</sub> However, in that study, colchicine was initiated only
on the third postoperative day; however, the highest AF incidence occurs on the
first 2 to 3 days after cardiac intervention.<sup><xref rid="r15" ref-type="bibr">15</xref></sup></p><p>This study aimed at assessing colchicine to prevent AF in patients undergoing
myocardial revascularization surgery.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Design and Participants</title><p>This is a prospective, randomized, open, single-center clinical assay, whose 140
participants were recruited from the Hospital Santa Casa de Miseric&#x000f3;rdia
de Curitiba.</p><p>This study followed the Declaration of Helsinki, which provides recommendations
to biomedical research involving human beings, and was submitted to the
Committee of Ethics in Research with Human Beings of the Pontif&#x000ed;cia
Universidade Cat&#x000f3;lica do Paran&#x000e1; (PUC-PR) (protocol 50883).</p></sec><sec><title>Inclusion Criteria</title><p>Patients willing and able to provide informed consent term were recruited. The
inclusion criteria were as follows: minimum age of 18 years; indication for
elective myocardial revascularization surgery; and sinus rhythm on the day prior
to surgery. Mean ages were 60.3 &#x000b1; 8.1 years and 61.5 &#x000b1; 10.3 years
in the control and colchicine groups (p = 0.44), respectively, and 45
participants were of the female sex, and 95, of the male sex.</p></sec><sec><title>Exclusion Criteria</title><p>The exclusion criteria were: contraindication to the study medication; previously
diagnosed AF or atrial flutter; need for heart valve surgery associated; severe
liver disease (aminotransferase levels increased more than 1.5-fold the normal
value); renal failure (creatinine &#x0003e; 2 mg/dL); known gastrointestinal
diseases; current colchicine treatment; cardiogenic shock; severe arrhythmias;
neoplasms; non-communicative patients; simultaneous use of antiarrhythmic drugs,
except for digoxin, beta-blockers and calcium channel blockers.</p></sec><sec><title>Intervention</title><p>From May 2012 to November 2013, 140 patients submitted to myocardial
revascularization surgery were randomized into two groups: control group, not
receiving the study medication; and therapeutic group, medicated with
colchicine. The therapeutic group received oral colchicine at the dose of 1 mg,
twice daily, in the preoperative period (initiated 24 hours before surgery),
followed by 0.5 mg, orally or nasogastrically, twice daily, until hospital
discharge. If the patient was admitted only 12 hours before surgery, colchicine
was administered orally, at a single dose of 1 mg, the night before surgery.
Clinical management and medications routinely used in both groups were not
changed.</p><p>The cardiac rhythm was defined as AF when no P wave was detected before the QRS
complex, and the heart rate was irregular. To be considered in this study, AF
episodes should last at least 5 minutes or, if shorter, they should have caused
hemodynamic instability. Atrial fibrillation was identified via
electrocardiography by using continuous cardiac monitoring and 12-lead
electrocardiogram (ECG) during intensive care unit (ICU) stay. After ICU
discharge, only daily record of 12-lead ECG.</p></sec><sec><title>Endpoints</title><p>The primary study endpoint was the AF-POMR rate in the colchicine and control
groups. Additional analyses included death from any cause, hospital length of
stay and postoperative infection.</p></sec><sec><title>Randomization</title><p>Patients were randomly assigned to the groups by use of a computer program (link:
<ext-link ext-link-type="uri" xlink:href="http://stattrek.com/statistics/random-number-generator.aspx">http://stattrek.com/statistics/random-number-generator.aspx</ext-link>).
Both participants and researchers were instructed on the treatment. Data were
collected by use of notification forms, manually completed by study
researchers.</p></sec><sec><title>Statistical Analysis</title><p>This study required 140 patients (69 in the control group and 71 in the
intervention group) to detect AF rates of 20% and 6%, respectively, with an 80%
power and p = 0.05 in both groups. The AF rate was estimated for both groups
based on the results of a randomized, placebo-controlled study, in which the AF
rate was significantly lower in the colchicine group than in the placebo group
(12% versus 22%, respectively, p = 0.021).<sup><xref rid="r6" ref-type="bibr">6</xref></sup></p><p>Quantitative variables were described as means, medians, minimum and maximum
values, and standard deviations. Qualitative variables were described as
frequencies and percentages. To compare the two groups regarding quantitative
variables, Student <italic>t</italic> test or nonparametric Mann-Whitney test
was used for independent samples. Regarding qualitative variables, the groups
were compared by using Fisher exact test or chi-square test. To compare the two
groups regarding time free from AF, log-rank test was used. Values of p &#x0003c;
0.05 indicated statistical significance. Data were assessed by using the
Statistica software, v.8.0.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patients' Characteristics</title><p>The patients' baseline characteristics were similar in both groups and are shown
in <xref ref-type="table" rid="t1">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients of this study</p></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Colchicine (n = 71)</th><th align="center" rowspan="1" colspan="1">Control (n = 69)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean age (mean &#x000b1; SD), years</td><td align="center" rowspan="1" colspan="1">61.5 &#x000b1; 10.3</td><td align="center" rowspan="1" colspan="1">60.3 &#x000b1; 8.1</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x0003c; 65 years (n = 96), n (%)</td><td align="center" rowspan="1" colspan="1">43 (60.6)</td><td align="center" rowspan="1" colspan="1">53 (76.8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x0003e; 65 years (n = 44), n (%)</td><td align="center" rowspan="1" colspan="1">28 (39.4)</td><td align="center" rowspan="1" colspan="1">16 (23.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex (n = 45), n (%)</td><td align="center" rowspan="1" colspan="1">22 (30.9)</td><td align="center" rowspan="1" colspan="1">23 (33.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex (n = 95), n (%)</td><td align="center" rowspan="1" colspan="1">49 (69.0)</td><td align="center" rowspan="1" colspan="1">46 (66.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Previous pathologies, n
(%)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">SA (n = 10)</td><td align="center" rowspan="1" colspan="1">3 (4.2)</td><td align="center" rowspan="1" colspan="1">7 (10.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">UA (n = 63)</td><td align="center" rowspan="1" colspan="1">32 (45.1)</td><td align="center" rowspan="1" colspan="1">31 (44.9)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD (n = 35)</td><td align="center" rowspan="1" colspan="1">21 (29.6)</td><td align="center" rowspan="1" colspan="1">14 (20.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">AMI (n = 32)</td><td align="center" rowspan="1" colspan="1">15 (21.1)</td><td align="center" rowspan="1" colspan="1">17 (24.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">SAH (n = 16)</td><td align="center" rowspan="1" colspan="1">63 (88.7)</td><td align="center" rowspan="1" colspan="1">61 (88.4)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking habit (n = 57)</td><td align="center" rowspan="1" colspan="1">23 (32.4)</td><td align="center" rowspan="1" colspan="1">34 (49.3)</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia (n = 88)</td><td align="center" rowspan="1" colspan="1">44 (61.9)</td><td align="center" rowspan="1" colspan="1">44 (63.8)</td><td align="center" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">DM (n = 72)</td><td align="center" rowspan="1" colspan="1">42 (59.2)</td><td align="center" rowspan="1" colspan="1">30 (43.5)</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous AMI (n = 31)</td><td align="center" rowspan="1" colspan="1">17 (23.9)</td><td align="center" rowspan="1" colspan="1">14 (20.3)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI (n = 20)</td><td align="center" rowspan="1" colspan="1">11 (15.5)</td><td align="center" rowspan="1" colspan="1">9 (13.1)</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous MR (n = 5)</td><td align="center" rowspan="1" colspan="1">3 (4.2)</td><td align="center" rowspan="1" colspan="1">2 (2.9)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">FH-CAD (n = 50)</td><td align="center" rowspan="1" colspan="1">23 (32.4)</td><td align="center" rowspan="1" colspan="1">27 (39.1)</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta-blocker (n = 72)</td><td align="center" rowspan="1" colspan="1">35 (50.0)</td><td align="center" rowspan="1" colspan="1">37 (53.6)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI (n = 63)</td><td align="center" rowspan="1" colspan="1">33 (46.5)</td><td align="center" rowspan="1" colspan="1">30 (43.5)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">ARB (n = 22)</td><td align="center" rowspan="1" colspan="1">12 (16.9)</td><td align="center" rowspan="1" colspan="1">10 (14.5)</td><td align="center" rowspan="1" colspan="1">0.82</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>SA: stable angina; UA: unstable angina; CAD: coronary artery disease;
AMI: acute myocardial infarction; SAH: systemic arterial
hypertension; DM: diabetes mellitus; PCI: percutaneous coronary
intervention; MR: myocardial revascularization; FH: family history;
ACEI: angiotensin-converting-enzyme inhibitor; ARB:
angiotensin-receptor-blocker.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Final Result</title><p>To assess the primary endpoint (AF-POMR in the colchicine and control groups),
AF-POMR episodes from the first postoperative day onward were considered. The
colchicine group showed no statistically significant reduction in AF incidence
as compared to the control group (7.0% versus 13.0%; p = 0.271; colchicine and
control, respectively). After beginning the intervention, the numbers of AF-POMR
events in the colchicine and control groups were 5 of 71 versus 9 of 69,
respectively (<xref ref-type="table" rid="t2">Tabele 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Endpoints of this study according to the colchicine and control
groups</p></caption><table frame="hsides" rules="groups"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Event</th><th style="border-bottom-width:thin;border-bottom-style:solid" align="center" rowspan="1" colspan="1">Colchicine</th><th style="border-bottom-width:thin;border-bottom-style:solid" align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="2" colspan="1">p</th><th style="border-bottom-width:thin;border-bottom-style:solid" align="center" rowspan="1" colspan="1">RRR, %</th></tr><tr><th align="center" rowspan="1" colspan="1">(n = 71)</th><th align="center" rowspan="1" colspan="1">(n = 69)</th><th align="center" rowspan="1" colspan="1">(95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1"><bold>Primary endpoint </bold></td></tr><tr><td align="left" rowspan="1" colspan="1">AF-POMR, %<xref ref-type="table-fn" rid="TFN03">*</xref></td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">13.0</td><td align="center" rowspan="1" colspan="1">0.271</td><td align="center" rowspan="1" colspan="1">46 (-53 a 81)</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Additional analyses</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Death from any cause, n (%)</td><td align="center" rowspan="1" colspan="1">4 (5.6)</td><td align="center" rowspan="1" colspan="1">7 (10.1)</td><td align="center" rowspan="1" colspan="1">0.363</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital length of stay, days</td><td align="center" rowspan="1" colspan="1">14.5 &#x000b1; 11.5</td><td align="center" rowspan="1" colspan="1">13.3 &#x000b1; 9.4</td><td align="center" rowspan="1" colspan="1">0.490</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative infection, n (%)</td><td align="center" rowspan="1" colspan="1">19 (26.8)</td><td align="center" rowspan="1" colspan="1">6 (8.7)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN02"><p>RRR: reduction in relative risk with colchicine; CI: confidence
interval; AF-POMR: atrial fibrillation in the postoperative period
of myocardial revascularization surgery.</p></fn><fn id="TFN03"><label>*</label><p>Calculated with Fisher exact test.</p></fn></table-wrap-foot></table-wrap><p>The colchicine and control groups showed no statistically significant difference
regarding the death from any cause rate (5.6% versus 10.1%, respectively; p =
0.363) and hospital length of stay (14.5 &#x000b1; 11.5 versus 13.3 &#x000b1; 9.4
days, respectively; p = 0,490). The colchicine group, however, had a higher
infection rate (26.8% versus 8.7%; p = 0.007) (<xref ref-type="table" rid="t2">Table 2</xref>).</p><p>The following clinical characteristics were identified in patients with AF-POMR
in both control and colchicine groups as compared to patients without AF-POMR
(<xref ref-type="table" rid="t3">Table 3</xref>): coronary care unit length
of stay (7.6 &#x000b1; 9.0 days versus 3.6 &#x000b1; 4.6 days, respectively; p =
0.008); use of extracorporeal circulation (ECC) during surgery (28.6% versus
39.7%, respectively; p = 0.566); postoperative beta-blocker use (100.0% versus
93.7%, respectively; p = 1.000); and use of blood products (21.4% versus 26.2%,
respectively; p = 1.000). Patients with AF-POMR had a longer coronary care unit
length of stay and no other significantly different characteristic.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of the clinical characteristics between patients with and
without atrial fibrillation (AF) in the postoperative period of
myocardial revascularization surgery in the control and colchicine
groups</p></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th style="border-bottom-width:thin;border-bottom-style:solid" align="center" colspan="3" rowspan="1">AF, n (%)</th></tr><tr><th align="center" rowspan="1" colspan="1">No (n = 126)</th><th align="center" rowspan="1" colspan="1">Yes (n = 14)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean age, years</td><td align="center" rowspan="1" colspan="1">60.4 &#x000b1; 9.2</td><td align="center" rowspan="1" colspan="1">65.6&#x000b1;9.1</td><td align="center" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x0003c; 65 years (n = 96)</td><td align="center" rowspan="1" colspan="1">88 (69.8)</td><td align="center" rowspan="1" colspan="1">8 (57.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x0003e; 65 years (n = 44)</td><td align="center" rowspan="1" colspan="1">38 (30.2)</td><td align="center" rowspan="1" colspan="1">6 (42.9)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex (n = 45)</td><td align="center" rowspan="1" colspan="1">41 (32.5)</td><td align="center" rowspan="1" colspan="1">4 (28.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex (n = 95)</td><td align="center" rowspan="1" colspan="1">85 (67.5)</td><td align="center" rowspan="1" colspan="1">10 (71.4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">SAH (n = 124)</td><td align="center" rowspan="1" colspan="1">114 (90.5)</td><td align="center" rowspan="1" colspan="1">10 (71.4)</td><td align="center" rowspan="1" colspan="1">0.057</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous MR (n = 5)</td><td align="center" rowspan="1" colspan="1">5 (3.9)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">DM (n = 72)</td><td align="center" rowspan="1" colspan="1">65 (51.6)</td><td align="center" rowspan="1" colspan="1">7 (50.0)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">CCU length of stay, days</td><td align="center" rowspan="1" colspan="1">3.6 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">7.6 &#x000b1; 9.0</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">ECC (n = 54)</td><td align="center" rowspan="1" colspan="1">50 (39.7)</td><td align="center" rowspan="1" colspan="1">4 (28.6)</td><td align="center" rowspan="1" colspan="1">0.566</td></tr><tr><td align="left" rowspan="1" colspan="1">Perioperative beta-blocker (n = 132)</td><td align="center" rowspan="1" colspan="1">118 (93.7)</td><td align="center" rowspan="1" colspan="1">14 (100.0)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of blood products (n = 36)</td><td align="center" rowspan="1" colspan="1">33 (26.2)</td><td align="center" rowspan="1" colspan="1">3 (21.4)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr></tbody></table><table-wrap-foot><fn id="TFN04"><p>SAH: systemic arterial hypertension; MR: myocardial revascularization
surgery; DM: diabetes mellitus; CCU: coronary care unit; ECC:
extracorporeal circulation.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The COPPS-POAF substudy has shown colchicine to be safe and effective to prevent
pericarditis and AF-POMR, reducing the incidence of AF (p = 0.021).<sup><xref rid="r6" ref-type="bibr">6</xref></sup> The present study showed no
statistically significant reduction in the AF-POMR rate, and one cause of that might
have been the reduced sample size.</p><p>In addition, the cardiac rhythm recording method (continuous cardiac monitoring and
12-lead ECG) might have missed some AF episodes, because the monitors used did not
allow data storage for later analysis. The AF-POMR episodes were recorded only when
they caused symptoms or hemodynamic change, or, if asymptomatic, when witnessed by
an attending physician.</p><p>The infection rate of the colchicine group was greater than that of the control
group. There is neither a randomized study nor a case report confirming the
relationship between colchicine use at therapeutic doses and the increase in the
number of infection cases. Our finding might have been random and related to the
reduced number of patients, which can be assessed in future studies.</p><p>Patients treated with colchicine remain hospitalized longer. That might not be
related to the drug itself, but rather to the infection rate, which, as previously
stated, was higher in the colchicine group. In addition, the COPPS-POAF substudy,
assessing a larger sample, has reported a reduction in the hospital length of stay
in the colchicine group as compared to that in the control group (9.4 &#x000b1; 3.7
versus 10.3 &#x000b1; 4.3 days; p = 0.040).<sup><xref rid="r6" ref-type="bibr">6</xref></sup></p><p>Of the 140 patients studied, 54 patients underwent myocardial revascularization
surgery with ECC, and 86 patients, without ECC. Hashemzadeh et al.,<sup><xref rid="r16" ref-type="bibr">16</xref></sup> assessing 939 patients submitted
to myocardial revascularization surgery, have reported AF-POMR in 38 patients of the
non-ECC group and in 93 patients of the ECC group (9.8% versus 16.7%, respectively,
p=0.002), showing an increase in the AF-POMR rate of patients undergoing surgery
with ECC. In the present study, most surgeries were performed without ECC, which
might explain the low AF-POMR rate found.</p><p>Similarly to the COPPS-POAF substudy, the incidence of death from any cause was not
significantly smaller in the colchicine group of this study.<sup><xref rid="r6" ref-type="bibr">6</xref></sup></p><p>Colchicine is a potent anti-inflammatory drug classically used to treat
pericarditis.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> Further
studies are required to confirm its real safety and efficacy in preventing
AF-POMR.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The use of colchicine to prevent AF-POMR showed no efficacy in the present study.</p><p>The authors deny any conflict of interest.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research, Analysis and interpretation of the data
and Statistical analysis: Zarpelon CS, Chomiski Netto M, Jorge JCM; Acquisition
of data: Zarpelon CS, Chomiski Netto M, Fabris CC, Desengrini D, Jardim MS,
Silva DG; Writing of the manuscript: Zarpelon CS; Critical revision of the
manuscript for intellectual content: Zarpelon CS, Jorge JCM,.</p></fn><fn fn-type="conflict"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This study is not associated with any thesis or dissertation work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank those who made this study possible, especially the Cardiac Surgery team and
the Clinical Cardiology teachers of the Hospital Santa Casa de Miseric&#x000f3;rdia
de Curitiba.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>AG</given-names></name><name><surname>Archbold</surname><given-names>A</given-names></name><name><surname>Helft</surname><given-names>G</given-names></name><name><surname>Paul</surname><given-names>EA</given-names></name><name><surname>Curzen</surname><given-names>NP</given-names></name><name><surname>Mills</surname><given-names>PG</given-names></name></person-group><article-title>Atrial fibrillation after coronary artery bypass surgery: a model
for preoperative risk stratification</article-title><source>Circulation</source><year>2000</year><volume>101</volume><issue>12</issue><fpage>1403</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">10736284</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>SG</given-names></name></person-group><article-title>Atrial fibrillation after cardiac surgery</article-title><source>Ann Card Anaesth</source><year>2010</year><volume>13</volume><issue>3</issue><fpage>196</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">20826960</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>LB</given-names></name><collab>CCS Atrial Fibrillation Guidelines Committee</collab><collab>Canadian Cardiovascular Society</collab></person-group><article-title>Atrial fibrillation guidelines 2010: prevention and treatment of
atrial fibrillation following cardiac surgery</article-title><source>Can J Cardiol</source><year>2011</year><volume>27</volume><issue>1</issue><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">21329866</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passannante</surname><given-names>AN</given-names></name></person-group><article-title>Prevention of atrial fibrillation after cardiac
surgery</article-title><source>Curr Opin Anaesthsiol</source><year>2011</year><volume>24</volume><issue>1</issue><fpage>58</fpage><lpage>63</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geovanini</surname><given-names>GR</given-names></name><name><surname>Alves</surname><given-names>RJ</given-names></name><name><surname>Brito</surname><given-names>GD</given-names></name><name><surname>Miguel</surname><given-names>GA</given-names></name><name><surname>Glauser</surname><given-names>VA</given-names></name><name><surname>Nakiri</surname><given-names>K</given-names></name></person-group><article-title>Postoperative atrial fibrillation after cardiac surgery: Who
should receive chemoprophylaxis?</article-title><source>Arq Bras cardiol</source><year>2009</year><volume>92</volume><issue>4</issue><fpage>326</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">19565143</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imazio</surname><given-names>M</given-names></name><name><surname>Brucato</surname><given-names>A</given-names></name><name><surname>Ferrazzi</surname><given-names>P</given-names></name><name><surname>Rovere</surname><given-names>ME</given-names></name><name><surname>Gandino</surname><given-names>A</given-names></name><name><surname>Cemin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Colchicine reduces postoperative atrial fibrillation: results of
the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS)
atrial fibrillation substudy</article-title><source>Circulation</source><year>2011</year><volume>124</volume><issue>21</issue><fpage>2290</fpage><lpage>2295</lpage><pub-id pub-id-type="pmid">22090167</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anselmi</surname><given-names>A</given-names></name><name><surname>Possati</surname><given-names>G</given-names></name><name><surname>Gaudino</surname><given-names>M</given-names></name></person-group><article-title>Postoperative inflammatory reaction and atrial fibrillation:
simple correlation or causation?</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>88</volume><issue>1</issue><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">19559266</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferro</surname><given-names>CR</given-names></name><name><surname>Oliveira</surname><given-names>DC</given-names></name><name><surname>Nunes</surname><given-names>FP</given-names></name><name><surname>Piegas</surname><given-names>LS</given-names></name></person-group><article-title>Postoperative atrial fibrillation after cardiac
surgery</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>1</issue><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19838472</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostagno</surname><given-names>C</given-names></name></person-group><article-title>Recent developments in pharmacologic prophylaxis of atrial
fibrillation in patients undergoing surgical
revascularization</article-title><source>Cardiovasc Hematol Agents Med Chem</source><year>2009</year><volume>7</volume><issue>2</issue><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">19355875</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Olgin</surname><given-names>JE</given-names></name><name><surname>Zipes</surname><given-names>DP</given-names></name></person-group><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><source>Tratado de doen&#x000e7;as cardiovasculares</source><chapter-title>Arritmias espec&#x000ed;ficas: diagn&#x000f3;stico e
tratamento</chapter-title><year>2010</year><edition>8&#x000aa; ed</edition><publisher-loc>Rio de Janeiro</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>863</fpage><lpage>931</lpage></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisel</surname><given-names>WH</given-names></name><name><surname>Rawn</surname><given-names>J</given-names></name><name><surname>Stevenson</surname><given-names>WG</given-names></name></person-group><article-title>Atrial fibrillation after cardiac surgery</article-title><source>Ann Intern Med</source><year>2001</year><volume>135</volume><issue>12</issue><fpage>106</fpage><lpage>173</lpage></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deftereos</surname><given-names>F</given-names></name><name><surname>Giannopoulos</surname><given-names>G</given-names></name><name><surname>Papoutsidakis</surname><given-names>N</given-names></name><name><surname>Panagopoulou</surname><given-names>V</given-names></name><name><surname>Kossyvakis</surname><given-names>C</given-names></name><name><surname>Raisakis</surname><given-names>K</given-names></name><etal/></person-group><article-title>Colchicine and the heart: pushing the envelope</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><issue>20</issue><fpage>1817</fpage><lpage>1825</lpage><pub-id pub-id-type="pmid">24036026</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Head</surname><given-names>BP</given-names></name><name><surname>Patel</surname><given-names>HH</given-names></name><name><surname>Roth</surname><given-names>DM</given-names></name><name><surname>Murray</surname><given-names>F</given-names></name><name><surname>Swaney</surname><given-names>JS</given-names></name><name><surname>Niesman</surname><given-names>IR</given-names></name><etal/></person-group><article-title>Microtubules and actin microfilaments regulate lipid
raft/caveolae localization of adenylyl cyclase signaling
components</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><issue>36</issue><fpage>26391</fpage><lpage>26399</lpage><pub-id pub-id-type="pmid">16818493</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malan</surname><given-names>D</given-names></name><name><surname>Gallo</surname><given-names>MP</given-names></name><name><surname>Bedendi</surname><given-names>I</given-names></name><name><surname>Biasin</surname><given-names>C</given-names></name><name><surname>Levi</surname><given-names>RC</given-names></name><name><surname>Alloatti</surname><given-names>G</given-names></name></person-group><article-title>Microtubules mobility affects the modulation of L-type I(Ca) by
muscarinic and beta-adrenergic agonists in guinea-pig cardiac
myocytes</article-title><source>J Mol Cell Cardiol</source><year>2003</year><volume>35</volume><issue>2</issue><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">12606260</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruins</surname><given-names>P</given-names></name><name><surname>te Velthuis</surname><given-names>H</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>AP</given-names></name><name><surname>Jansen</surname><given-names>PG</given-names></name><name><surname>van Hardevelt</surname><given-names>FW</given-names></name><name><surname>de Beaumont</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Activation of the complement system during and after
cardiopulmonary bypass surgery: postsurgery activation involves C-reactive
protein and is associated with postoperative arrhythmia</article-title><source>Circulation</source><year>1997</year><volume>96</volume><issue>10</issue><fpage>3542</fpage><lpage>3548</lpage><pub-id pub-id-type="pmid">9396453</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemzadeh</surname><given-names>K</given-names></name><name><surname>Dehdilani</surname><given-names>M</given-names></name><name><surname>Dehdilani</surname><given-names>M</given-names></name></person-group><article-title>Does off-pump coronary artery bypass reduce the prevalence of
atrial fibrillation?</article-title><source>J Cardiovasc Thorac Res</source><year>2013</year><volume>5</volume><issue>2</issue><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">24251010</pub-id></element-citation></ref></ref-list></back></article>